Literature DB >> 3994895

Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

M Jurima, T Inaba, D Kadar, W Kalow.   

Abstract

The genetically controlled mephenytoin p(4')-hydroxylation capacity was determined in 118 Caucasians and 70 Orientals. After an oral dose of 50 or 100 mg of racemic mephenytoin, the amount of p(4')-hydroxymephenytoin in 24 h urine was measured by gas chromatography. Bimodal distribution was found with 9/70 (13%) Orientals and 5/118 (4%) Caucasians demonstrating deficient p(4')-hydroxylation. The statistically significant difference between Orientals and Caucasians (P less than 0.05) was accounted for by the high incidence of poor metabolizers among the Japanese subjects, 7/31 (23%). The frequency among Chinese subjects, 2/39 (5%), was similar to the frequency among Caucasians.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994895      PMCID: PMC1463809          DOI: 10.1111/j.1365-2125.1985.tb02673.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Human alcohol dehydrogenase ADH2 and ADH3 polymorphisms in ethnic Chinese and Indians of West Malaysia.

Authors:  Y S Teng; S Jehan; L E Lie-Injo
Journal:  Hum Genet       Date:  1979       Impact factor: 4.132

2.  A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.

Authors:  C Mbanefo; E A Bababunmi; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  Xenobiotica       Date:  1980-11       Impact factor: 1.908

3.  A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.

Authors:  T Inaba; M Nakano; S V Otton; W A Mahon; W Kalow
Journal:  Can J Physiol Pharmacol       Date:  1984-07       Impact factor: 2.273

4.  Liver alcohol dehydrogenase and aldehyde dehydrogenase in the Japanese: isozyme variation and its possible role in alcohol intoxication.

Authors:  S Harada; S Misawa; D P Agarwal; H W Goedde
Journal:  Am J Hum Genet       Date:  1980-01       Impact factor: 11.025

5.  A method for studying drug metabolism in populations: racial differences in amobarbital metabolism.

Authors:  W Kalow; B K Tang; D Kadar; L Endrenyi; F Y Chan
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

Review 6.  Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.

Authors:  G A Ellard
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

7.  Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.

Authors:  W Kalow; S V Otton; D Kadar; L Endrenyi; T Inaba
Journal:  Can J Physiol Pharmacol       Date:  1980-09       Impact factor: 2.273

8.  Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.

Authors:  N M Woolhouse; B Andoh; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

9.  A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.

Authors:  A Mahgoub; J R Idle; R L Smith
Journal:  Xenobiotica       Date:  1979-01       Impact factor: 1.908

10.  Diphenhydramine in Orientals and Caucasians.

Authors:  R Spector; A K Choudhury; C K Chiang; M J Goldberg; M M Ghoneim
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

View more
  28 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects.

Authors:  R Setiabudy; K Chiba; M Kusaka; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

3.  CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Authors:  Margareta Ramsjö; Eleni Aklillu; Lilleba Bohman; Magnus Ingelman-Sundberg; Hyung-Keun Roh; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-05-25       Impact factor: 2.953

Review 4.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 5.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

6.  Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.

Authors:  R R Meehan; J R Gosden; D Rout; N D Hastie; T Friedberg; M Adesnik; R Buckland; V van Heyningen; J Fletcher; N K Spurr
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

7.  Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.

Authors:  H Miwa; H Misawa; T Yamada; A Nagahara; K Ohtaka; N Sato
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Mephenytoin hydroxylation in the Cuna Amerindians of Panama.

Authors:  T Inaba; L F Jorge; T D Arias
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

Review 10.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.